These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 31005943)

  • 21. Immediate versus delayed insertion of an etonogestrel releasing implant at medical abortion-a randomized controlled equivalence trial.
    Hognert H; Kopp Kallner H; Cameron S; Nyrelli C; Jawad I; Heller R; Aronsson A; Lindh I; Benson L; Gemzell-Danielsson K
    Hum Reprod; 2016 Nov; 31(11):2484-2490. PubMed ID: 27664217
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Second- and Third-Trimester Medical Abortion Providers and Services in 2019: Results From the Canadian Abortion Provider Survey.
    Renner R; Ennis M; Guilbert E; Roy G; Barrett J
    J Obstet Gynaecol Can; 2022 Jun; 44(6):690-699. PubMed ID: 35183788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abortion health services in Canada: Results of a 2012 national survey.
    Norman WV; Guilbert ER; Okpaleke C; Hayden AS; Steven Lichtenberg E; Paul M; White KO; Jones HE
    Can Fam Physician; 2016 Apr; 62(4):e209-e217. PubMed ID: 28192276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Are US health professionals likely to prescribe mifepristone or methotrexate?
    Koenig JD; Tapias MP; Hoff T; Stewart FH
    J Am Med Womens Assoc (1972); 2000; 55(3 Suppl):155-60. PubMed ID: 10846327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mifepristone (RU486) in Australian pharmacies: the ethical and practical challenges.
    Lee RY; Moles R; Chaar B
    Contraception; 2015 Jan; 91(1):25-30. PubMed ID: 25248673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The future of abortion is now: Mifepristone by mail and in-clinic abortion access in the United States.
    Mark A; Foster AM; Perritt J
    Contraception; 2021 Jul; 104(1):38-42. PubMed ID: 33844980
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of mifepristone for medical abortion in Australia, 2006-2009.
    de Costa CM
    Med J Aust; 2011 Feb; 194(4):206-7. PubMed ID: 21401466
    [No Abstract]   [Full Text] [Related]  

  • 28. Clinical uses of mifepristone: an update for women's health practitioners.
    Beal MW; Simmonds K
    J Midwifery Womens Health; 2002; 47(6):451-60. PubMed ID: 12484667
    [TBL] [Abstract][Full Text] [Related]  

  • 29. When Off-label is Illegal: Implications of Mandating the FDA-approved Protocol for Mifepristone-induced Abortions.
    Britton L; Bryant A
    Womens Health Issues; 2015; 25(5):433-5. PubMed ID: 26169217
    [No Abstract]   [Full Text] [Related]  

  • 30. Prospective study of home use of mifepristone and misoprostol for medical abortion up to 10weeks of pregnancy in Kazakhstan.
    Platais I; Tsereteli T; Grebennikova G; Lotarevich T; Winikoff B
    Int J Gynaecol Obstet; 2016 Sep; 134(3):268-71. PubMed ID: 27352735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medical termination for pregnancy in early first trimester (≤ 63 days) using combination of mifepristone and misoprostol or misoprostol alone: a systematic review.
    Abubeker FA; Lavelanet A; Rodriguez MI; Kim C
    BMC Womens Health; 2020 Jul; 20(1):142. PubMed ID: 32635921
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical applications of mifepristone.
    Tang OS; Ho PC
    Gynecol Endocrinol; 2006 Dec; 22(12):655-9. PubMed ID: 17162706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The relationship of contextual factors to women's perceptions of medical abortion.
    Harvey SM; Beckman LJ; Roberts Branch M
    Health Care Women Int; 2002; 23(6-7):654-65. PubMed ID: 12418986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medical abortion in Canada: behind the times.
    Dunn S; Cook R
    CMAJ; 2014 Jan; 186(1):13-4. PubMed ID: 24277708
    [No Abstract]   [Full Text] [Related]  

  • 35. "I'll just deal with this on my own": a qualitative exploration of experiences with self-managed abortion in the United States.
    Raifman S; Ralph L; Biggs MA; Grossman D
    Reprod Health; 2021 May; 18(1):91. PubMed ID: 33947413
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of medical abortion using mifepristone and buccal misoprostol through 63 days.
    Gatter M; Cleland K; Nucatola DL
    Contraception; 2015 Apr; 91(4):269-73. PubMed ID: 25592080
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacy workers in Nepal can provide the correct information about using mifepristone and misoprostol to women seeking medication to induce abortion.
    Tamang A; Puri M; Lama K; Shrestha P
    Reprod Health Matters; 2015 Feb; 22(44 Suppl 1):104-15. PubMed ID: 25702074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early medical abortion--available and safe.
    de Costa CM; Carrette M
    Med J Aust; 2012 Sep; 197(5):257-8. PubMed ID: 22938106
    [No Abstract]   [Full Text] [Related]  

  • 39. Availability of medical abortion medicines in eight countries: a descriptive analysis of key findings and opportunities.
    Grossman A; Prata N; Williams N; Ganatra B; Lavelanet A; Läser L; Asmani C; Elamin H; Ouedraogo L; Rahman MM; Conneh-Duworko MJ; Tehoungue BZ; Chanza H; Phiri H; Bhattarai B; Dhakal NP; Ojo OA; Afolabi K; Kabuteni TJ; Hailu BG; Moses F; Dlamini-Nqeketo S; Zulu T; Rehnström Loi U
    Reprod Health; 2023 Apr; 20(Suppl 1):58. PubMed ID: 37041543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Antiprogestin to clinical use].
    Heikinheimo O
    Duodecim; 2000; 116(12):1261-2. PubMed ID: 11988960
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.